Biopharma
ByU.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term Oncology Optionality for Bristol-Myers Squibb and BioNTech?
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
Is Gilead’s Experimental HIV Treatment Matching the Efficacy of Its Blockbuster Drug in Late-Stage Trials?
Foster City, California — Gilead Sciences has reported that its experimental HIV treatment has met the primary goal…
Is Sanofi Strengthening Its Adult Vaccine Strategy with a $2.2 Billion Dynavax Deal?
Paris, France Sanofi has taken a major step to strengthen its adult vaccines portfolio by announcing a $2.2…
Has Sanofi’s Dupixent Been Approved for Pediatric Asthma in Japan?
Tokyo, Japan – December 23, 2025 Sanofi and Regeneron have received regulatory approval in Japan for Dupixent (dupilumab)…
